<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01871792</url>
  </required_header>
  <id_info>
    <org_study_id>PRINCIPLE-II</org_study_id>
    <nct_id>NCT01871792</nct_id>
  </id_info>
  <brief_title>Preventive Effect of Pitavastatin on Contrast-Induced Nephropathy in Patients With Renal Dysfunction</brief_title>
  <official_title>Preventive Effect of the PRetreatment With pItavastatiN on Contrast-Induced Nephropathy in Patients With RenaL Dysfunction UndErgoing Coronary Angiography/Intervention (PRINCIPLE-II Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gachon University Gil Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gangnam Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Health Insurance Service Ilsan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Myongji Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bundang CHA Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Inje University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dankook University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eulji General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Gachon University Gil Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Contrast-induced nephropathy (CIN) is a well-recognized complication of radiographic contrast
      administration and is associated with increased short- and long-term mortality. Previous
      strategies including forced diuresis with diuretics or mannitol, intravenous administration
      of fenoldopam or dobutamine, and postprocedure hemodialysis to prevent CIN have been largely
      unsuccessful. In addition, the use of N-acetylcysteine to prevent CIN has yielded conflicting
      outcomes.

      A review of a large insurance database and retrospective study have shown that statins
      therapy is associated with a lower incidence of CIN after percutaneous coronary intervention.
      The preventive effect of statins on CIN may be attributed to direct pleiotropic effects on
      the vascular wall such as improvement of endothelial dysfunction, anti-inflammatory or
      anti-oxidative effect. However, recent randomized trial could not demonstrate the preventive
      effect of statin on CIN in patients with chronic kidney disease.

      Thus, we will investigate the preventive effect of pitavastatin on CIN in patient with renal
      dysfunction undergoing coronary angiography or intervention.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">February 2014</completion_date>
  <primary_completion_date type="Anticipated">February 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of contrast-induced nephropathy</measure>
    <time_frame>48 hours</time_frame>
    <description>Contrast-induced nephropathy is defined as either a greater than 25% increase of serum creatinine or an absolute increase in serum creatinine of 0.5 mg/dL after coronary angiography or intervention.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak level of serum creatinine</measure>
    <time_frame>48 hours</time_frame>
    <description>Peak level of serum creatinine within less than 48 hours after coronary angiography or intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum cystatin-C level</measure>
    <time_frame>24 hours</time_frame>
    <description>Absolute level of serum cystatin-C 24 hours after coronary angiography/intervention and Difference level of serum cystatin-C before and after coronary angiography/intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum neutrophil-gelatinase-associated lipocalin(NGAL) level</measure>
    <time_frame>4 hours</time_frame>
    <description>Absolute level of serum NGAL level 4 hours after coronary angiography/intervention and difference level before and after coronary angiography/intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>an expected average of 5 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical events</measure>
    <time_frame>1 month</time_frame>
    <description>Composites of death, myocardial infarction, stroke or need for dialysis therapy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">404</enrollment>
  <condition>Contrast-induced Nephropathy</condition>
  <arm_group>
    <arm_group_label>Pitavastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pitavastatin 4 mg/day for 7 days before coronary angiography/intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablet for 7 days before coronary angiography/intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pitavastatin</intervention_name>
    <arm_group_label>Pitavastatin</arm_group_label>
    <other_name>Livalo®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sugar pill manufactured to mimic Pitavastatin 4 mg tablet</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 19 years

          -  Need for coronary angiography or intervention in patients with typical symptoms for
             angina or myocardial infarction, or documented myocardial ischemia at non-invasive
             studies including ECG, treadmill ECG test, heart spect or coronary CT angiography

          -  Estimated glomerular filtration rate ≤60 mL/min

          -  Informed consent

        Exclusion Criteria:

          -  Need for primary percutaneous coronary intervention or emergent intervention in
             patients with myocardial infarction

          -  Allergic reaction for contrast agent (Visipaque) or statin

          -  Contraindication for contrast agent (Visipaque) or statin

          -  Shock status fron any cause including cardiogenic shock

          -  Statin use before enrollment (Enrollment after 2 weeks of wash-out period)

          -  Exposure of contrast agent within 7 days before enrollment

          -  Pregnancy or Expectation for pregnancy in women of childbearing age

          -  Heart failure (NYHA class ≥3 or left ventricular ejection fraction &lt; 40%)

          -  Acute renal injury

          -  Dialysis therapy

          -  Mechanical ventilator

          -  Life expectancy &lt; 6 months

          -  Non-steroidal anti-inflammatory drug, dopamine, mannitol or N-acetylcysteine, ascorbic
             acid within 48 hours before and after coronary angiography/intervention

          -  Severe hepatic dysfunction

          -  Eisenmenger syndrome or idiopathic pulmonary hypertension

          -  Renal artery angioplasty within 6 months

          -  Single functioning kidney

          -  Kidney transplantation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Woong Chul Kang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gachon University Gil Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Woong Chul Kang, M.D.</last_name>
    <phone>+82-32-460-3663</phone>
    <email>kangwch@gilhospital.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Gachon University Gil Hospital</name>
      <address>
        <city>Incheon</city>
        <zip>405-760</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Woong Chul Kang, M.D.</last_name>
      <phone>+82-32-460-3663</phone>
      <email>kangwch@gilhospital.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 25, 2013</study_first_submitted>
  <study_first_submitted_qc>June 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2013</study_first_posted>
  <last_update_submitted>June 4, 2013</last_update_submitted>
  <last_update_submitted_qc>June 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 7, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Gachon University Gil Medical Center</investigator_affiliation>
    <investigator_full_name>Woong Chol Kang</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Contrast-induced nephropathy</keyword>
  <keyword>Prevention</keyword>
  <keyword>Statin</keyword>
  <keyword>Pitavastatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pitavastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

